Clinical Consultations™: Targeting NASH: Expert Perspectives on Evolving Treatment Strategies
November 13, 2019
November 13, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
Supported by an educational grant from Intercept Pharmaceuticals, Inc.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Nurses — maximum of 1.5 contact hours.
All other healthcare professionals completing this course will be issued a statement of participation.
This online educational activity is directed toward gastroenterologists, hepatologists, endocrinologists, diabetologists, primary care physicians, and any other healthcare professionals involved in the treatment of NASH.
Nonalcoholic steatohepatitis (NASH) is a severe type of fatty liver disease characterized by the accumulation of fat in the liver with inflammation and ballooning, with or without fibrosis and absent of significant alcohol consumption. The inflammation can progress to cirrhosis, portal hypertension, liver cancer, and eventual liver failure. NASH is projected to become the leading indication for liver transplant in the very near future. Fueled by the obesity epidemic and increasing prevalence of type 2 diabetes, NASH is considered the hepatic expression of metabolic syndrome. Because of low awareness of patients at risk of disease progression, the development of NASH is frequently not detected until cirrhosis is established. Current treatment consists of lifestyle interventions.
During this Clinical Consultations™, 2 expert faculty will review risk factors for fatty liver disease and the diagnostic tools used to determine which patients are at risk of disease progression. They will then discuss the latest evidence on novel compounds in clinical trials and conclude with practical application of points discussed through case presentations.
Benefits of Participating
- Increase competence using laboratory tests and imaging studies to assess and monitor liver damage
- Learn when a liver biopsy is indicated for definitive diagnosis of NASH
- Gain awareness of emerging treatments with targeted pathophysiologic approaches
- Expand diagnostic acumen of fatty liver disease through case presentation and discussion
Upon completion of this activity, participants should be able to:
- Apply a case-based approach to clinical assessment of NASH, including appropriate screening, diagnostic evaluation, and treatment
- Identify patients with nonalcoholic fatty liver disease (NAFLD) at increased risk of the development of NASH and those with NASH at risk of progression to advanced fibrosis
- Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
- Evaluate clinical trial data, mechanisms of action, and efficacy of emerging therapeutic agents targeting NASH
Rohit Loomba, MD, MHSc
Director, NAFLD Research Center
Vice Chief, Division of Gastroenterology
University of California, San Diego
La Jolla, CA
Nikolaos Pyrsopoulos, MD, PhD, MBA
Professor and Chief, Division of Gastroenterology and Hepatology
Medical Director, Liver Transplantation
Rutgers New Jersey Medical School
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Credit Designation Statement
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour(s).
Disclosures of Conflicts of Interest
Rohit Loomba, MD, MHSc
- Grant/Research Support: Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma, Prometheus, Siemens
- Consultant or Advisory Board: Arrowhead Pharmaceuticals, AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cirius, CohBar, Conatus, Eli Lilly, Galmed Pharmaceuticals, Gemphire, Gilead, Glympse Bio, GNI, GRI Bio, Intercept, Ionis, Janssen, Merck, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Sanofi, Siemens, Viking Therapeutics
- Other: Liponexus, Inc (cofounder).
Nikolaos Pyrsopoulos, MD, PhD, MBA
- Grant/Research Support: AbbVie, Bayer, BeiGene, Conatus, Genfit, Gilead, Grifols, Hologic, Intercept, Mallinckrodt, Novartis, Prometheus, Salix, Zydus
- Consultant: Bayer, Novartis.
The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
Method of Participation
Instructions for This Activity and Receiving Credit
- You will need to log in to participate in the activity.
- Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
- At the end of the activity, educational content/audio files will be available for your reference.
- In order to receive a CME/CE certificate, you must complete the activity.
- Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Disclosure of Unlabeled Use
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.